Work in our lab is aimed at understanding the pathophysiological mechanisms leading to neurodegeneration in two types of motor neuron diseases (MND): the childhood onset spinal muscular atrophy and the adult-onset Amyotrophic Lateral Sclerosis (ALS). We are more specifically investigating whether changes in cellular metabolism could precipitate neuronal death across a wide range of MND models. Ultimately, we hope to identify much-needed novel therapeutic targets for these devastating diseases.
Energy metabolism in motor neuron diseases
About the project
Funder(s)
Medical Research Council, Motor Neurone Disease Association
Publication(s)
Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in multiple models of amyotrophic lateral sclerosis
EBioMed. 2022;83:104202 2022 Aug 10
Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine.
Cell Rep Med. 2021;2(7) 2021 Jul 20
Primary location
Edinburgh
Principal Investigator
Other people involved
Professor Tom Gillingwater (Edinburgh)
Kim Morris (Research Assistant)
Other people involved
Professor Tom Gillingwater (Edinburgh)
Kim Morris (Research Assistant)
